LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

FDA Approves Use of New Zika Assay to Screen Blood Supply

By LabMedica International staff writers
Posted on 16 Aug 2016
Image: A Zika virus capsid, colored per chains (Photo courtesy of Manuel Almagro Rivas / Wikimedia).
Image: A Zika virus capsid, colored per chains (Photo courtesy of Manuel Almagro Rivas / Wikimedia).
The US Food & Drug Administration (FDA) has approved the use of a new Zika virus assay to screen the USA blood supply under its Investigational New Drug (IND) study protocol. Blood banks will use the test on an automated nucleic acids technology (NAT) platform to screen donated blood in potential endemic areas.

The Procleix Zika virus assay, co-developed by leading blood safety partners Hologic, Inc. (Marlborough, MA, USA) and Grifols (Emeryville, CA, USA), will be used on the automated Procleix Panther system. Procleix Panther automates all aspects of NAT-based blood screening on a single, integrated platform. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. The system has received regulatory approvals in countries around the world, and is in development for use in the US.

Prominent blood centers will use the assay to screen donated blood collected in potential endemic areas of the southern US, and may expand testing to other areas of the U.S. if the virus continues to spread.

"The American Red Cross is pleased to participate in the Procleix Zika Virus assay investigational study, which will allow us to begin blood donor testing for Zika virus early this summer in areas most likely to have local mosquito transmission of the virus," said Susan Stramer, PhD, vice president, Scientific Affairs, American Red Cross, "Working together, we remain committed to ensuring the safety and availability of the US blood supply for patients in need."

"Zika virus is a rapidly growing threat to public health," said Tom West, division president, Diagnostic Solutions, Hologic, the “announcement demonstrates our ability to quickly develop molecular diagnostics in response to new and emerging pathogens." "As a global leader in Transfusion Medicine," said Carsten Schroeder, president, Grifols Diagnostic Division, "Grifols is proud to serve blood banks and healthcare professionals working around the world to ensure patients receive safe blood transfusions."

Related Links:
Hologic
Grifols
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more